Study of envafolimab for bile duct or gallbladder cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug called envafolimab for people with advanced bile duct or gallbladder cancer. The goal is to see if it can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (unresectable or spread) gallbladder cancer or cholangiocarcinoma.
- You either have not received prior cancer treatment for advanced disease, or you completed adjuvant chemotherapy more than 6 months ago.
- Your liver function is relatively good (Child-Pugh class A or better B).
- You are generally able to take care of yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new drug (envafolimab) combined with standard chemotherapy and a common cholesterol medicine (simvastatin) for advanced bile duct and gallbladder cancer. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a combination of two medications (envafolimab and surufatinib) plus a procedure that uses heat to destroy cancer cells inside the bile ducts. It is for people with bile duct or gallbladder cancer that cannot be removed surgically and who are not candidates for or do not want chemotherapy.
This trial tests a new drug called mitazalimab, which helps the immune system fight cancer, combined with standard chemotherapy (FOLFOX) for people whose bile duct or gallbladder cancer did not respond to or stopped responding to initial immunotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth better than chemotherapy alone.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.